Sun Pharmaceutical Industries Ltd has announced the acquisition of Innovcare Lifesciences Private Limited for around ₹271.2 crore, expanding its portfolio in pharmaceutical and wellness products.
The transaction involves the acquisition of 100% of the outstanding shares of Innovcare and is expected to be completed on or before July 31, 2026, subject to customary closing conditions.
Shares of Sun Pharma were trading around ₹1,842.20, up 0.2% during the day. The company has a market capitalisation of approximately ₹4.42 lakh crore.
Details of the acquisition
According to the company’s exchange filing:
- Acquirer: Sun Pharmaceutical Industries Ltd
- Target company: Innovcare Lifesciences Private Limited
- Stake being acquired: 100%
- Deal value: Approximately ₹271.2 crore
- Mode of payment: Cash
- Expected completion: On or before July 31, 2026
Sun Pharma said the transaction is not a related-party deal and that the promoter group has no interest in Innovcare.
About Innovcare Lifesciences
Mumbai-based Innovcare Lifesciences is engaged in:
- Marketing and distribution of pharmaceutical products
- Nutraceutical products
- Cosmeceutical products
The company has reported steady growth in recent years.
Revenue from operations
- FY26: ₹94.06 crore
- FY25: ₹86.09 crore
- FY24: ₹80.93 crore
Strategic rationale
The acquisition will help Sun Pharma strengthen its domestic business and increase its exposure to fast-growing healthcare categories.
The company expects the deal to enhance its portfolio in:
- Pharmaceuticals
- Nutraceuticals
- Cosmeceuticals
These segments have seen rising demand due to:
- Greater focus on preventive healthcare
- Increasing consumer awareness
- Growing demand for wellness products
- Expansion of premium skincare categories
The addition of Innovcare’s products and distribution network could also provide cross-selling opportunities and improve Sun Pharma’s reach among:
- Hospitals
- Pharmacies
- Healthcare professionals
About Sun Pharma
Founded in 1993, Sun Pharmaceutical Industries is India’s largest pharmaceutical company and one of the world’s leading specialty generic drug manufacturers.
The company develops and markets:
- Branded formulations
- Generic medicines
- Specialty drugs
- Active Pharmaceutical Ingredients (APIs)
- Consumer healthcare products
Sun Pharma has manufacturing facilities across multiple countries and sells products in more than 100 countries.
The proposed acquisition forms part of the company’s strategy to expand into adjacent healthcare segments with higher growth potential.
TL;DR
Sun Pharma has signed an agreement to acquire Innovcare Lifesciences for approximately ₹271.2 crore. The deal, expected to close by July 31, 2026, will strengthen the company’s portfolio in pharmaceuticals, nutraceuticals and cosmeceuticals.
AI Summary
- Sun Pharma will acquire Innovcare Lifesciences for ₹271.2 crore.
- The transaction involves the purchase of a 100% stake.
- The deal is expected to close by July 31, 2026.
- Innovcare reported FY26 revenue of ₹94.06 crore.
- The acquisition will expand Sun Pharma’s presence in nutraceutical and cosmeceutical segments.
